Boston Scientific Corporation $BSX Stock: Deltec Asset Management LLC Decreases Stake

Deltec Asset Management LLC cut its holdings in Boston Scientific Corporation (NYSE:BSX) by 92.4% in the third quarter, Holdings Channel reports. The fund owned 6,500 shares of the medical equipment provider’s stock after selling 79,400 shares during the quarter. Deltec Asset Management LLC’s holdings in Boston Scientific were worth $284,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Clal Insurance Enterprises Holdings Ltd bought a new stake in shares of Boston Scientific in the 1st quarter valued at about $28,000. Cassaday & Co Wealth Management LLC purchased a new stake in shares of Boston Scientific in the 1st quarter worth approximately $32,000. Measured Wealth Private Client Group LLC boosted its stake in shares of Boston Scientific by 244.9% during the first quarter. Measured Wealth Private Client Group LLC now owns 545 shares of the medical equipment provider’s stock valued at $34,000 after purchasing an additional 387 shares in the last quarter. Kelleher Financial Advisors bought a new position in shares of Boston Scientific during the second quarter valued at approximately $25,000. Finally, Nvwm LLC increased its holdings in Boston Scientific by 526.2% during the third quarter. Nvwm LLC now owns 645 shares of the medical equipment provider’s stock valued at $28,000 after buying an additional 542 shares during the period. 89.07% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages recently commented on BSX. Evercore reduced their price objective on shares of Boston Scientific from $65.00 to $52.00 and set an “outperform” rating for the company in a research note on Wednesday, October 7th. BTIG Research dropped their target price on Boston Scientific from $60.00 to $56.00 and set a “buy” rating on the stock in a research report on Wednesday, September 9th. Wells Fargo & Company cut their price target on Boston Scientific from $50.00 to $48.00 and set an “equal weight” rating on the stock in a report on Wednesday, September 23rd. Oppenheimer reduced their price target on Boston Scientific from $85.00 to $65.00 and set an “outperform” rating for the company in a research report on Monday, September 21st. Finally, UBS Group decreased their price objective on Boston Scientific from $74.00 to $67.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $68.07.

Boston Scientific Price Performance

NYSE BSX opened at $45.60 on Tuesday. The firm’s fifty day simple moving average is $45.54 and its two-hundred day simple moving average is $58.24. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43. Boston Scientific Corporation has a 12-month low of $41.38 and a 12-month high of $105.65. The firm has a market capitalization of $66.08 billion, a P/E ratio of 18.46, a P/E/G ratio of 1.10 and a beta of 0.58.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%. The business had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. During the same period in the prior year, the firm posted $0.75 earnings per share. The business’s quarterly revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Analysts forecast that Boston Scientific Corporation will post 3.24 EPS for the current fiscal year.

Insider Buying and Selling

In other Boston Scientific news, CEO Michael Mahoney bought 186,240 shares of Boston Scientific stock in a transaction that occurred on Monday, August 3rd. The shares were bought at an average cost of $48.33 per share, with a total value of $9,000,979.20. Following the transaction, the chief executive officer directly owned 1,590,024 shares of the company’s stock, valued at approximately $76,845,859.92. This represents a 13.27% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director David Habiger purchased 2,100 shares of the firm’s stock in a transaction on Wednesday, August 5th. The stock was acquired at an average price of $47.59 per share, with a total value of $99,939.00. Following the completion of the purchase, the director owned 17,160 shares of the company’s stock, valued at $816,644.40. The trade was a 13.94% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have acquired a total of 194,522 shares of company stock worth $9,385,210 in the last ninety days. 0.34% of the stock is owned by insiders.

Boston Scientific Company Profile

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.